Abstract
Short QT syndrome (SQTS) is a malignant heart disorder defined by the presence of ventricular arrhythmias causing syncope and sudden cardiac arrest. The prevalence in the pediatric population is 0.05%. Quinidine is an established agent for pharmacological prophylaxis in SQTS patients, but can also terminate an electrical storm.
K E Y W O R D S
arrhythmia, electrical storm, quinidine, short QT resonance imaging, and coronary angiography were normal. The patient went on to have a positive programmed ventricular stimulation for inducible ventricular tachycardia and underwent an implantable cardioverter defibrillator implantation. Genetic testing did not detect any mutations. A short QT interval is usually considered if QTc is ≤340 ms, 1,2 and a diagnosis of SQTS was established. After 5 months, the patient presented with electrical storm with 16 successive episodes of Torsade de pointes that degenerate to ventricular fibrillation (Figure 2) . The episodes were induced by a premature ventricular beat due to R/T phenomenon. Esmolol and amiodarone intravenous infusion were proven ineffective, as well as sotalol therapy. The patient received a 500 mg oral loading dose of quinidine and then 250 mg two times daily. Quinidine led to the rapid disappearance of premature beats and arrhythmia episodes.
Quinidine can normalize the QT interval, leading to significant QT prolongation, a longer ventricular effective refractory period, and is an established preventive therapy for SQTS. 1, 2 To the best of our knowledge, only a few cases of electrical storm in SQTS have been described in the pediatric population, and this is the first case demonstrating the beneficial effect of quinidine in the suppression of electrical storm in SQTS patients. 
